STOCK TITAN

Bolt Biotherapeutics’ Gujrathi gets 72,766 common shares

The merger terms provided 1.6413 BOLT common shares or common-stock equivalents per Prana common share; no cash purchase price was paid for Series D Preferred.

(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Sheila Gujrathi, Bolt Biotherapeutics' Chief Strategy Officer and a director, reported direct receipt of 72,766 common shares and 2,763.833 Series D Preferred shares when her Prana Therapies shares converted at the merger closing on October 23, 2026. SilverArc Private Fund I, L.P.'s Prana holdings converted into 13,055 common shares and 495.874 Series D Preferred shares; Gujrathi disclaims beneficial ownership of the fund's securities except to the extent of any pecuniary interest. Each Series D Preferred share is convertible into 1,000 common shares, subject to conditions including requisite stockholder approval.

Insider GUJRATHI SHEILA
Role Chief Strategy Officer
Type Security Shares Price Value
Other Series D Preferred Stock F4, F1, F2 2,763.833 -- --
Other Series D Preferred Stock F4, F1, F2, F3 495.874 -- --
Grant/Award Common Stock F1, F2 72,766 $0.00 $0.00
Grant/Award Common Stock F1, F2, F3 13,055 $0.00 $0.00
Holdings After Transaction: Series D Preferred Stock — 2,763.833 contracts (Direct); Series D Preferred Stock — 495.874 contracts (Indirect, By SilverArc Private Fund I, L.P.); Common Stock — 72,766 shares (Direct); Common Stock — 13,055 shares (Indirect, By SilverArc Private Fund I, L.P.)
Footnotes (4)
  1. F1. Received in exchange for shares of common stock of Prana Therapies, Inc. ("Prana") pursuant to the Agreement and Plan of Merger dated October 23, 2026 (the "Merger Agreement") by and among the Issuer, Prana, Prince Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer ("Merger Sub I"), Prince Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer ("Merger Sub II"). Each outstanding share of Prana common stock was converted into the right to receive 1.6413 shares of the Issuer's common stock or common-stock equivalents, consisting of Issuer's common stock and Series D Convertible Preferred Stock ("Series D Preferred") convertible at a rate of 1,000 shares of Issuer's common stock per share of Series D Preferred. No cash purchase price was paid for the Series D Preferred received as merger consideration.
  2. F2. Upon closing of the merger on October 23, 2026, Prana shares held directly by the Reporting Person converted into 72,766 shares of Issuer's common stock and 2,763.833 shares of Series D Preferred. Prana shares held by SilverArc Private Fund I, L.P. converted into 13,055 shares of Issuer's common stock and 495.874 shares of Series D Preferred. The 495.874 shares of Series D Preferred constitute merger consideration
  3. F3. The Reporting Person is Co-Portfolio Manager and has membership interest in SilverArc Private Capital I, LLC (Ultimate General Partner), SilverArc Private Capital I, LP (General Partner), and SilverArc Private Capital Management I, LP (Management Company) for SilverArc Private Fund I, L.P. The Reporting Person may not be deemed to have voting or investment power over the shares held of record by SilverArc Private Fund I, LP. The Reporting Person disclaims beneficial ownership of the Non-Derivative and Derivative securities held of record by SilverArc Private Fund I, L.P., except to the extent of any pecuniary interest therein.
  4. F4. Each share of Series D Preferred is convertible into 1,000 shares of the Issuer's common stock, subject to the conditions set forth in the Certificate of Designation, including receipt of the requisite stockholder approval. The Series D Preferred has no expiration date.
Direct common shares received 72,766 shares Merger consideration on October 23, 2026
Direct Series D Preferred shares received 2,763.833 shares Merger consideration on October 23, 2026
Common shares underlying direct Series D Preferred 2,763,833 shares Convertible at 1,000 common shares per Series D Preferred share, subject to stated conditions
SilverArc Private Fund I, L.P. common shares received 13,055 shares Merger consideration on October 23, 2026
SilverArc Private Fund I, L.P. Series D Preferred shares received 495.874 shares Merger consideration on October 23, 2026
Common shares underlying SilverArc Private Fund I, L.P. Series D Preferred 495,874 shares Convertible at 1,000 common shares per Series D Preferred share, subject to stated conditions
Merger exchange ratio 1.6413 BOLT common shares or common-stock equivalents per Prana common share Merger consideration
Series D Preferred financial
"convertible at a rate of 1,000 shares of the Issuer's common stock per share of Series D Preferred"
common-stock equivalents financial
"Issuer's common stock or common-stock equivalents"
Certificate of Designation technical
"conditions set forth in the Certificate of Designation"
A certificate of designation is a formal document that spells out the specific rights and rules attached to a particular class or series of stock, usually preferred shares. Think of it as a rulebook or menu that lists dividend terms, liquidation priority, conversion or redemption rights and any special voting protections; investors use it to judge how much income, control or downside protection those shares will provide compared with other securities.
pecuniary interest financial
"except to the extent of any pecuniary interest therein"
Agreement and Plan of Merger technical
"Agreement and Plan of Merger dated October 23, 2026"
An Agreement and Plan of Merger is a formal document where two companies agree to combine into one, outlining how the process will happen. It’s like a step-by-step plan for merging, and it matters because it shows both sides have agreed on the details before the official transition takes place.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What BOLT shares did Sheila Gujrathi receive in the Prana merger?

On October 23, 2026, Gujrathi's directly held Prana shares converted into 72,766 common shares and 2,763.833 Series D Preferred shares. SilverArc Private Fund I, L.P.'s Prana holdings converted into 13,055 common shares and 495.874 Series D Preferred shares. Gujrathi disclaims beneficial ownership of the fund-held securities except to the extent of any pecuniary interest.

What were the BOLT exchange terms for Prana shares?

Each outstanding Prana common share converted into the right to receive 1.6413 BOLT common shares or common-stock equivalents. No cash purchase price was paid for the Series D Preferred received as merger consideration.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
GUJRATHI SHEILA

(Last)(First)(Middle)
900 CHESAPEAKE DRIVE

(Street)
REDWOOD CITY CALIFORNIA 94063

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Bolt Biotherapeutics, Inc. [ BOLT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Strategy Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
10/23/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock10/23/2026A(1)(2)72,766A$0(1)(2)72,766D
Common Stock10/23/2026A(1)(2)13,055A$0(1)(2)13,055IBy SilverArc Private Fund I, L.P.(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Series D Preferred Stock(4)10/23/2026 (4)J2,763.833 (4) (4)Common Stock2,763,833(1)(2)2,763.833D
Series D Preferred Stock(4)10/23/2026J(4)495.874 (4) (4)Common Stock495,874(1)(2)495.874IBy SilverArc Private Fund I, L.P.(3)
Explanation of Responses:
1. Received in exchange for shares of common stock of Prana Therapies, Inc. ("Prana") pursuant to the Agreement and Plan of Merger dated October 23, 2026 (the "Merger Agreement") by and among the Issuer, Prana, Prince Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer ("Merger Sub I"), Prince Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer ("Merger Sub II"). Each outstanding share of Prana common stock was converted into the right to receive 1.6413 shares of the Issuer's common stock or common-stock equivalents, consisting of Issuer's common stock and Series D Convertible Preferred Stock ("Series D Preferred") convertible at a rate of 1,000 shares of Issuer's common stock per share of Series D Preferred. No cash purchase price was paid for the Series D Preferred received as merger consideration.
2. Upon closing of the merger on October 23, 2026, Prana shares held directly by the Reporting Person converted into 72,766 shares of Issuer's common stock and 2,763.833 shares of Series D Preferred. Prana shares held by SilverArc Private Fund I, L.P. converted into 13,055 shares of Issuer's common stock and 495.874 shares of Series D Preferred. The 495.874 shares of Series D Preferred constitute merger consideration
3. The Reporting Person is Co-Portfolio Manager and has membership interest in SilverArc Private Capital I, LLC (Ultimate General Partner), SilverArc Private Capital I, LP (General Partner), and SilverArc Private Capital Management I, LP (Management Company) for SilverArc Private Fund I, L.P. The Reporting Person may not be deemed to have voting or investment power over the shares held of record by SilverArc Private Fund I, LP. The Reporting Person disclaims beneficial ownership of the Non-Derivative and Derivative securities held of record by SilverArc Private Fund I, L.P., except to the extent of any pecuniary interest therein.
4. Each share of Series D Preferred is convertible into 1,000 shares of the Issuer's common stock, subject to the conditions set forth in the Certificate of Designation, including receipt of the requisite stockholder approval. The Series D Preferred has no expiration date.
/s/ Sheila Gujrathi10/27/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading